Medical guideline

首页肿瘤学指南检索结果

检索结果

按发表年份

共搜索到7条与Combination有关的结果

Chemotherapy in Combination with Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline

2021年发布于 American Society of Clinical Oncology 卷第期 所属人体系统：呼吸 | 鼻咽癌

American Society of Clinical Oncology

Nasopharyngeal Carcinoma Stage II to IVA Chemotherapy Radiotherapy Combination Definitive-intent Treatment
指南简介 原文链接
ESMO Recommendations on Predictive Biomarker Testing for Homologous Recombination Deficiency and PARP Inhibitor Benefit in Ovarian Cancer

2020年发布于 Ann Oncol 31卷第12期 所属人体系统：生殖 | 卵巢肿瘤

European Society for Medical Oncology

BRCA Genomic Scar Assays Homologous Recombination Deficiency (HRD) Poly-ADP Ribose Inhibitors (PARPi).
指南简介 原文链接
Diagnostic Value of Imaging (ultrasonography, Doppler, CT, MR, PET-CT) for the Diagnosis of a Suspicious Ovarian Mass and Staging of Ovarian, Tubal Or Primary Peritoneal Cancer: Article Drafted from the French Guidelines in Oncology Entitled `Initial Man

2019年发布于 Gynecol Obstet Fertil Senol 47卷第2期 所属人体系统：生殖 | 输卵管癌

FRANCOGYN (Groupe Français De Recherche En Chirurgie Oncologique Et Gynécologique) Au CNGOF (Collège National Des Gynécologues Obstétriciens Français) À La SFOG (Société Française D’oncologie Gynécologique Et Au Groupe GINECO-ARCAGY (Groupe D’investigateurs Nationaux Pour L’étude Des Cancers Ovariens Et Du Sein – Association De Recherche Sur Les Cancers Dont Gynécologiques) Et Sont Labellisées Par L’INCa (Institut National Du Cancer).

Transvaginal Ultrasound Is the First-line Examination Allowing Characterizing 80 to 90% of Adnexal Masses (LP1). If Performed by an Expert a Subjective Analysis Is Optimal. If Performed by a Non-expert Combining the Use of Simple Rules with Subjective Analysis Can Achieve the Diagnostic Performance of an Expert (LP1). Whichever the Chosen Model (subjective Analysis by an Expert Or Combination of the Simple Rules with a Subjective Analysis by a Non-expert) a Second-line Examination Will Have to Be Proposed in the Complex Or Indeterminate Cases (about 20% of the Masses) (grade A). the Best-performing Second-line Test for Characterization Is Pelvic MRI (LP1). If Read by an Expert a Pathological Hypothesis Can Or Should Be Suggested (grade D). in Case of Non-expert Reading the Use of the ADNEXMR Score Allows a Reliable Assessment of the Positive Predictive Value of Malignancy to Guide the Patient Towards the Best Management (gradeC). for Preoperative Assessment and Evaluation of Resectability of Ovarian Fallopian Tube Or Primary Peritoneal Cancer It Is Recommended to Perform a Chest Abdomen and Pelvis CT with Contrast Agent Injection (LP2 Grade B). in the Event of a Contraindication to the Injection of Iodinated Contrast Agent (severe Renal Insufficiency GFR <30mL/min) an Abdomen and Pelvis MRI Completed with a Non-injected Chest CT May Be Proposed (LP3 Grade C). by Analogy the Same Examinations Are Recommended to Evaluate the Disease after Neo-adjuvant Chemotherapy (LP3 Recommendation Grade C). Further Studies Will Be Required to Determine Whether PET-CT Provides Better Lymph Node Assessment Before Retroperitoneal and Pelvic Lymphadenectomy. PET-CT May Be Used to Eliminate Lymph Node Involvement in the Absence of Suspicious Lymph Nodes on Morphological Examination (LP3 Grade C). the Report Should Specify the Localizations Leading to a Risk of Incomplete Cytoreductive Surgery and Lesions Outside the Field Explored During Surgery.
指南简介 原文链接
Diagnostic Value of Imaging (ultrasonography, Doppler, CT, MR, PET-CT) for the Diagnosis of a Suspicious Ovarian Mass and Staging of Ovarian, Tubal Or Primary Peritoneal Cancer: Article Drafted from the French Guidelines in Oncology Entitled `Initial Man

2019年发布于 Gynecol Obstet Fertil Senol 47卷第2期 所属人体系统：生殖 | 卵巢肿瘤

FRANCOGYN (Groupe Français De Recherche En Chirurgie Oncologique Et Gynécologique) Au CNGOF (Collège National Des Gynécologues Obstétriciens Français) À La SFOG (Société Française D’oncologie Gynécologique Et Au Groupe GINECO-ARCAGY (Groupe D’investigateurs Nationaux Pour L’étude Des Cancers Ovariens Et Du Sein – Association De Recherche Sur Les Cancers Dont Gynécologiques) Et Sont Labellisées Par L’INCa (Institut National Du Cancer).

Transvaginal Ultrasound Is the First-line Examination Allowing Characterizing 80 to 90% of Adnexal Masses (LP1). If Performed by an Expert a Subjective Analysis Is Optimal. If Performed by a Non-expert Combining the Use of Simple Rules with Subjective Analysis Can Achieve the Diagnostic Performance of an Expert (LP1). Whichever the Chosen Model (subjective Analysis by an Expert Or Combination of the Simple Rules with a Subjective Analysis by a Non-expert) a Second-line Examination Will Have to Be Proposed in the Complex Or Indeterminate Cases (about 20% of the Masses) (grade A). the Best-performing Second-line Test for Characterization Is Pelvic MRI (LP1). If Read by an Expert a Pathological Hypothesis Can Or Should Be Suggested (grade D). in Case of Non-expert Reading the Use of the ADNEXMR Score Allows a Reliable Assessment of the Positive Predictive Value of Malignancy to Guide the Patient Towards the Best Management (gradeC). for Preoperative Assessment and Evaluation of Resectability of Ovarian Fallopian Tube Or Primary Peritoneal Cancer It Is Recommended to Perform a Chest Abdomen and Pelvis CT with Contrast Agent Injection (LP2 Grade B). in the Event of a Contraindication to the Injection of Iodinated Contrast Agent (severe Renal Insufficiency GFR <30mL/min) an Abdomen and Pelvis MRI Completed with a Non-injected Chest CT May Be Proposed (LP3 Grade C). by Analogy the Same Examinations Are Recommended to Evaluate the Disease after Neo-adjuvant Chemotherapy (LP3 Recommendation Grade C). Further Studies Will Be Required to Determine Whether PET-CT Provides Better Lymph Node Assessment Before Retroperitoneal and Pelvic Lymphadenectomy. PET-CT May Be Used to Eliminate Lymph Node Involvement in the Absence of Suspicious Lymph Nodes on Morphological Examination (LP3 Grade C). the Report Should Specify the Localizations Leading to a Risk of Incomplete Cytoreductive Surgery and Lesions Outside the Field Explored During Surgery.
指南简介 原文链接
Diagnostic Value of Imaging (ultrasonography, Doppler, CT, MR, PET-CT) for the Diagnosis of a Suspicious Ovarian Mass and Staging of Ovarian, Tubal Or Primary Peritoneal Cancer: Article Drafted from the French Guidelines in Oncology Entitled `Initial Man

2019年发布于 Gynecol Obstet Fertil Senol 47卷第2期 所属人体系统：其他 | 腹膜肿瘤

FRANCOGYN (Groupe Français De Recherche En Chirurgie Oncologique Et Gynécologique) Au CNGOF (Collège National Des Gynécologues Obstétriciens Français) À La SFOG (Société Française D’oncologie Gynécologique Et Au Groupe GINECO-ARCAGY (Groupe D’investigateurs Nationaux Pour L’étude Des Cancers Ovariens Et Du Sein – Association De Recherche Sur Les Cancers Dont Gynécologiques) Et Sont Labellisées Par L’INCa (Institut National Du Cancer).

Transvaginal Ultrasound Is the First-line Examination Allowing Characterizing 80 to 90% of Adnexal Masses (LP1). If Performed by an Expert a Subjective Analysis Is Optimal. If Performed by a Non-expert Combining the Use of Simple Rules with Subjective Analysis Can Achieve the Diagnostic Performance of an Expert (LP1). Whichever the Chosen Model (subjective Analysis by an Expert Or Combination of the Simple Rules with a Subjective Analysis by a Non-expert) a Second-line Examination Will Have to Be Proposed in the Complex Or Indeterminate Cases (about 20% of the Masses) (grade A). the Best-performing Second-line Test for Characterization Is Pelvic MRI (LP1). If Read by an Expert a Pathological Hypothesis Can Or Should Be Suggested (grade D). in Case of Non-expert Reading the Use of the ADNEXMR Score Allows a Reliable Assessment of the Positive Predictive Value of Malignancy to Guide the Patient Towards the Best Management (gradeC). for Preoperative Assessment and Evaluation of Resectability of Ovarian Fallopian Tube Or Primary Peritoneal Cancer It Is Recommended to Perform a Chest Abdomen and Pelvis CT with Contrast Agent Injection (LP2 Grade B). in the Event of a Contraindication to the Injection of Iodinated Contrast Agent (severe Renal Insufficiency GFR <30mL/min) an Abdomen and Pelvis MRI Completed with a Non-injected Chest CT May Be Proposed (LP3 Grade C). by Analogy the Same Examinations Are Recommended to Evaluate the Disease after Neo-adjuvant Chemotherapy (LP3 Recommendation Grade C). Further Studies Will Be Required to Determine Whether PET-CT Provides Better Lymph Node Assessment Before Retroperitoneal and Pelvic Lymphadenectomy. PET-CT May Be Used to Eliminate Lymph Node Involvement in the Absence of Suspicious Lymph Nodes on Morphological Examination (LP3 Grade C). the Report Should Specify the Localizations Leading to a Risk of Incomplete Cytoreductive Surgery and Lesions Outside the Field Explored During Surgery.
指南简介 原文链接
Practical Consensus Recommendations Regarding the Use of Hormonal Therapy in Metastatic Breast Cancer

2018年发布于 South Asian J Cancer 7卷第2期 所属人体系统：生殖 | 乳腺肿瘤

无

Aromatase Inhibitor ESR1 Testing Combination Endocrine Therapy Evorolimus Exemestane Fulvestrant Palbociclib
指南简介 原文链接
Practical Consensus Recommendations Regarding the Management of HER2 Neu Positive Metastatic Breast Cancer

2018年发布于 South Asian J Cancer 7卷第2期 所属人体系统：生殖 | 乳腺肿瘤

无

Capecitabine TDM1 Combination Systemic Therapy Docetaxel Lapatinib Personalized Modification Pertuzumab Trastuzumab
指南简介 原文链接

人体系统

共搜索到7条 与Combination有关的结果

2021年 发布于 American Society of Clinical Oncology 卷 第期 所属人体系统： 呼吸 | 鼻咽癌

American Society of Clinical Oncology

2020年 发布于 Ann Oncol 31卷 第12期 所属人体系统： 生殖 | 卵巢肿瘤

European Society for Medical Oncology

2019年 发布于 Gynecol Obstet Fertil Senol 47卷 第2期 所属人体系统： 生殖 | 输卵管癌

2019年 发布于 Gynecol Obstet Fertil Senol 47卷 第2期 所属人体系统： 生殖 | 卵巢肿瘤

2019年 发布于 Gynecol Obstet Fertil Senol 47卷 第2期 所属人体系统： 其他 | 腹膜肿瘤

2018年 发布于 South Asian J Cancer 7卷 第2期 所属人体系统： 生殖 | 乳腺肿瘤

无

2018年 发布于 South Asian J Cancer 7卷 第2期 所属人体系统： 生殖 | 乳腺肿瘤

无

共搜索到7条与Combination有关的结果

2021年发布于 American Society of Clinical Oncology 卷第期 所属人体系统：呼吸 | 鼻咽癌

2020年发布于 Ann Oncol 31卷第12期 所属人体系统：生殖 | 卵巢肿瘤

2019年发布于 Gynecol Obstet Fertil Senol 47卷第2期 所属人体系统：生殖 | 输卵管癌

2019年发布于 Gynecol Obstet Fertil Senol 47卷第2期 所属人体系统：生殖 | 卵巢肿瘤

2019年发布于 Gynecol Obstet Fertil Senol 47卷第2期 所属人体系统：其他 | 腹膜肿瘤

2018年发布于 South Asian J Cancer 7卷第2期 所属人体系统：生殖 | 乳腺肿瘤

2018年发布于 South Asian J Cancer 7卷第2期 所属人体系统：生殖 | 乳腺肿瘤